Abstract:<p>BACKGROUD & AIMS: Although SARS-CoV-2 infects gastrointestinal tissues, little is known about the roles of gut commensal microbes in susceptibility to and severity of infection. We investigated changes in fecal microbiomes of patients with SARS-CoV-2 infection during hospitalization and associations with severity and fecal shedding of virus.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">METHODS</h3><p>We performed shotgun metagenomic sequencing analyses of fecal samples from 15 patients with COVID-19 in Hong Kong, from February 5 through March 17, 2020. Fecal samples were collected 2 or 3 times per week from time of hospitalization until discharge; disease was categorized as mild (no radiographic evidence of pneumonia), moderate (pneumonia was present), severe (respiratory rate ≥30/min, or oxygen saturation ≤93% when breathing ambient air), or critical (respiratory failure requiring mechanical ventilation, shock, or organ failure requiring intensive care). We compared microbiome data with those from 6 subjects with community-acquired pneumonia and 15 healthy individuals (controls). We assessed gut microbiome profiles in association with disease severity and changes in fecal shedding of SARS-CoV-2.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">RESULTS</h3><p>Patients with COVID-19 had significant alterations in fecal microbiomes compared with controls, characterized by enrichment of opportunistic pathogens and depletion of beneficial commensals, at time of hospitalization and at all timepoints during hospitalization. Depleted symbionts and gut dysbiosis persisted even after clearance of SARS-CoV-2 (determined from throat swabs) and resolution of respiratory symptoms. The baseline abundance of <em>Coprobacillus</em>, <em>Clostridium ramosum</em>, and <em>Clostridium hathewayi</em> correlated with COVID-19 severity; there was an inverse correlation between abundance of <em>Faecalibacterium prausnitzii</em> (an anti-inflammatory bacterium) and disease severity. Over the course of hospitalization, <em>Bacteroides dorei</em>, <em>Bacteroides thetaiotaomicron</em>, <em>Bacteroides massiliensis</em>, and <em>Bacteroides ovatus,</em> which downregulate expression of ACE2 in murine gut, correlated inversely with SARS-CoV-2 load in fecal samples from patients.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">CONCLUSIONS</h3><p>In a pilot study of 15 patients with COVID-19, we found persistent alterations in the fecal microbiome during the time of hospitalization, compared with controls. Fecal microbiota alterations were associated with fecal levels of SARS-CoV-2 and COVID-19 severity. Strategies to alter the intestinal microbiota might reduce disease severity.</p>

Gut microbiome dysbiosis in antibiotic-treated COVID-19 patients is associated with microbial translocation and bacteremia

Dysbiosis of oropharyngeal microbiome and antibiotic resistance in hospitalized COVID‐19 patients

Alterations in Gut Microbiota of Patients With COVID-19 During Time of Hospitalization

SARS-CoV-2 infection is associated with intestinal permeability, systemic inflammation, and microbial dysbiosis in hospitalized patients

Dysbiosis of gut microbiota in patients with severe COVID-19

Gut microbiota from patients with COVID-19 cause alterations in mice that resemble post-COVID symptoms

Impact of SARS-CoV-2 infection on respiratory and gut microbiome stability: a metagenomic investigation in long-term-hospitalized COVID-19 patients

Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19

Gut microbiota dysbiosis is associated with altered tryptophan metabolism and dysregulated inflammatory response in COVID-19

Characterization of respiratory microbial dysbiosis in hospitalized COVID-19 patients

Antibiotics and probiotics impact gut antimicrobial resistance gene reservoir in COVID-19 patients

BACTERIAL TRANSLOCATION: MICROBIOTA-INTESTINE-LUNG AXIS AND PRO-INFLAMMATORY STATUS IN THE SEVERITY OF COVID-19

Persistent intestinal dysbiosis after SARS-CoV-2 infection in Brazilian patients

Impact of SARS-CoV2 infection on gut microbiota dysbiosis

Gut Microbiota and COVID-19: Potential Implications for Disease Severity

Antibiotic use, gut microbiome and COVID-19 risk: a review

Gut and airway microbiota dysbiosis and their role in COVID-19 and long-COVID

Gut microbiota in COVID-19: key microbial changes, potential mechanisms and clinical applications

Bacterial and Fungal Gut Dysbiosis and Clostridium difficile in COVID-19: A Review

Gut microbiome dysbiosis and immune activation correlate with somatic and neuropsychiatric symptoms in COVID-19 patients

Altered infective competence of the human gut microbiome in COVID-19